Publications
2015
Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.
Rumi E,
Milosevic JD,
Selleslag D,
Casetti I,
Lierman E,
Pietra D,
Cavalloni C,
Bellini M,
Milanesi C,
Dambruoso I,
Astori C,
Kralovics R,
Vandenberghe P,
Cazzola M.
Ann Hematol. 2015 Nov;94(11):1927-8. doi: 10.1007/s00277-015-2451-7. Epub 2015 Jul 23.
2015
Whole exome sequencing identifies novel MPL and JAK2 mutations in triple negative myeloproliferative neoplasms.
Milosevic Feenstra JD,
Nivarthi H,
Gisslinger H,
Leroy E,
Rumi E,
Chachoua I,
Bagienski K,
Kubesova B,
Pietra D,
Gisslinger B,
Milanesi C,
Jäger R,
Chen D,
Berg T,
Schalling M,
Schuster M,
Bock C,
Constantinescu SN,
Cazzola M,
Kralovics R.
Blood. 2015 Sep 30. pii: blood-2015-07-661835.
2015
Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.
Marty C,
Pecquet C,
Nivarthi H,
Elkhoury M,
Chachoua I,
Tulliez M,
Villeval JL,
Raslova H,
Kralovics R,
Constantinescu SN,
Plo I,
Vainchenker W.
Blood. 2015 Nov 25. pii: blood-2015-11-679571.
2015
NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation.
Licciardello MP,
Müllner MK,
Dürnberger G,
Kerzendorfer C,
Boidol B,
Trefzer C,
Sdelci S,
Berg T,
Penz T,
Schuster M,
Bock C,
Kralovics R,
Superti-Furga G,
Colinge J,
Nijman SM,
Kubicek S.
Oncogene. 2015 Jul;34(29):3780-90. doi: 10.1038/onc.2014.319. Epub 2014 Sep 29.
2015
Germline RBBP6 mutations in familial myeloproliferative neoplasms.
Harutyunyan AS,
Giambruno R,
Krendl C,
Stukalov A,
Klampfl T,
Berg T,
Chen D,
Milosevic Feenstra JD,
Jäger R,
Gisslinger B,
Gisslinger H,
Rumi E,
Passamonti F,
Pietra D,
Müller AC,
Parapatics K,
Breitwieser FP,
Herrmann R,
Colinge J,
Bennett KL,
Superti-Furga G,
Cazzola M,
Hammond E,
Kralovics R.
Blood. 2015 Nov 16. pii: blood-2015-09-668673.
2015
Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.
Gisslinger H,
Zagrijtschuk O,
Buxhofer-Ausch V,
Thaler J,
Schloegl E,
Gastl GA,
Wolf D,
Kralovics R,
Gisslinger B,
Strecker K,
Egle A,
Melchardt T,
Burgstaller S,
Willenbacher E,
Schalling M,
Them NC,
Kadlecova P,
Klade C,
Greil R.
Blood. 2015 Oct 8;126(15):1762-9. doi: 10.1182/blood-2015-04-637280. Epub 2015 Aug 10.
2015
Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.
Chachoua I,
Pecquet C,
El-Khoury M,
Nivarthi H,
Albu RI,
Marty C,
Gryshkova V,
Defour JP,
Vertenoeil G,
Ngo A,
Koay A,
Raslova H,
Courtoy PJ,
Choong ML,
Plo I,
Vainchenker W,
Kralovics R,
Constantinescu SN.
Blood. 2015 Dec 14. pii: blood-2015-11-681932.
2015
Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.
Am J Hematol. 2015 Apr;90(4):288-94. doi: 10.1002/ajh.23928. Epub 2015 Mar 2.
2015
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.
Tapper W,
Jones AV,
Kralovics R,
Harutyunyan AS,
Zoi K,
Leung W,
Godfrey AL,
Guglielmelli P,
Callaway A,
Ward D,
Aranaz P,
White HE,
Waghorn K,
Lin F,
Chase A,
Baxter EJ,
Maclean C,
Nangalia J,
Chen E,
Evans P,
Short M,
Jack A,
Wallis L,
Oscier D,
Duncombe AS,
Schuh A,
Mead AJ,
Griffiths M,
Ewing J,
Gale RE,
Schnittger S,
Haferlach T,
Stegelmann F,
Döhner K,
Grallert H,
Strauch K,
Tanaka T,
Bandinelli S,
Giannopoulos A,
Pieri L,
Mannarelli C,
Gisslinger H,
Barosi G,
Cazzola M,
Reiter A,
Harrison C,
Campbell P,
Green AR,
Vannucchi A,
Cross NC.
Nat Commun. 2015 Apr 7;6:6691. doi: 10.1038/ncomms7691.
2015
Allelic imbalance in CALR somatic mutagenesis.
Harutyunyan AS,
Jäger R,
Chen D,
Berg T,
Rumi E,
Gisslinger B,
Pietra D,
Gisslinger H,
Cazzola M,
Kralovics R.
Leukemia. 2015 Jan 8. doi: 10.1038/leu.2015.3
